Kinnate Biopharma
Kinnate Biopharma is dedicated to developing innovative cancer treatments by targeting specific proteins called kinases. They focus on creating targeted therapies for cancers with known genetic drivers, intrinsic resistance, or that develop resistance over time. Their approach involves structure-based drug design, prioritizing high selectivity, optimized pharmaceutical properties, broad genetic coverage, and overcoming resistance. They aim to develop drug candidates with lasting clinical responses, focusing on well-defined patient populations, and have built strong collaborations with research institutions. Their pipeline includes proprietary small molecule candidates targeting validated cancer drivers, with ongoing clinical trials for compounds like exarafenib and KIN-3248.
Industries
Nr. of Employees
medium (51-250)
Kinnate Biopharma
Patents
Products
Exarafenib (KIN-2787)
An orally administered investigational small molecule pan-RAF inhibitor targeting BRAF and NRAS-driven alterations in advanced solid tumors.
KIN-3248
A small-molecule kinase inhibitor targeting cancer-associated alterations in FGFR2 and FGFR3 genes, aimed at treating intrahepatic cholangiocarcinoma and urothelial carcinoma.
KIN-8741
A highly selective c-MET inhibitor designed to cover broad mutational coverage, including acquired resistance mutations, primarily focused on non-small cell lung cancer.
CDK4 Inhibitor
A potentially brain-penetrant, selective CDK4 inhibitor currently in the drug candidate exploration phase for treating adult solid tumors.
Exarafenib (KIN-2787)
An orally administered investigational small molecule pan-RAF inhibitor targeting BRAF and NRAS-driven alterations in advanced solid tumors.
KIN-3248
A small-molecule kinase inhibitor targeting cancer-associated alterations in FGFR2 and FGFR3 genes, aimed at treating intrahepatic cholangiocarcinoma and urothelial carcinoma.
KIN-8741
A highly selective c-MET inhibitor designed to cover broad mutational coverage, including acquired resistance mutations, primarily focused on non-small cell lung cancer.
CDK4 Inhibitor
A potentially brain-penetrant, selective CDK4 inhibitor currently in the drug candidate exploration phase for treating adult solid tumors.
News & Updates
Kinnate Biopharma closed a Series C financing round of $98 million to advance multiple precision oncology drug candidates into the clinic.
Kinnate Biopharma appointed Nima Farzan as CEO, expanding its leadership team.
An article discussing Kinnate's plans to move its lead RAF inhibitor into clinical trials.
Kinnate closed a Series B financing round of $74.5 million to fund its drug development programs.
Fount Therapeutics, a subsidiary of Kinnate, secured $22 million in Series A funding to develop treatments in various therapeutic areas.
Kinnate Biopharma closed a Series C financing round of $98 million to advance multiple precision oncology drug candidates into the clinic.
Kinnate Biopharma appointed Nima Farzan as CEO, expanding its leadership team.
An article discussing Kinnate's plans to move its lead RAF inhibitor into clinical trials.
Kinnate closed a Series B financing round of $74.5 million to fund its drug development programs.
Fount Therapeutics, a subsidiary of Kinnate, secured $22 million in Series A funding to develop treatments in various therapeutic areas.